Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated his 'Outperform' rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a price target of $21.
September 06, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has reiterated an 'Outperform' rating on Olema Pharmaceuticals and maintained a price target of $21.
The reiteration of an 'Outperform' rating by a reputable analyst like Matthew Biegler from Oppenheimer is a positive signal for the stock. The maintained price target of $21 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100